Evolocumab and Cardiovascular Risk in High-Risk Diabetes: What VESALIUS-CV Found 8th August 2026 by Living Diabetes Editorial A prespecified VESALIUS-CV analysis found fewer major cardiovascular events with evolocumab in selected adults with high-risk diabetes, but the results are not a recommendation for everyone with diabetes.
Cholesterol and Diabetes: LDL, Triglycerides, HDL, and Heart Risk 6th June 202620th March 2026 by Living Diabetes Editorial Team Plain-language cholesterol guide for people with diabetes, explaining LDL, HDL, triglycerides, heart risk, testing, medicines, and questions.
